Organization
CHU Rouen
6 abstracts
Abstract
Bevacizumab in combination with chemotherapy for treating patients with advanced RET+ non-small cell lung cancer.Org: CHI De Creteil, Créteil, European Hospital Georges Pompidou, Hospital General Universitario Gregorio Marañon, Azienda Ospedaliera di Perugia,
Abstract
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.Org: Hôpitaux Nord-Ouest, Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).Org: Institut du Thorax Curie Montsouris, Institut Curie, Paris, and UVSQ, Paris Saclay University, Versailles, France, Institut Curie, Saint Cloud, France, Univ Rouen Normandie, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
Predicting non-small cell lung cancer response to immune checkpoint inhibitors with machine learning based on heterogeneous biomarkers.Org: INRIA, Sophia Antipolis, Centre Antoine Lacassagne, Center hospitalier Princesse-Grace, Univ Rouen Normandie,
Abstract
Real-life efficacy of nivolumab plus ipilimumab combination in untreated, unresectable malignant pleural mesotheliomas: Result of French early access program—MESOIMMUNE – GFPC 04-2021.Org: HIA SAINTE ANNE, Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
2007 UPDATE OF THE FRENCH NATIONAL GUIDELINES FOR THE USE IN DAILY PRACTICE OF TNF-BLOCKERS IN PEOPLE SUFFERING FROM RHEUMATOID ARTHRITISOrg: University of Paris 6, Pitié Salpêtrière Hospital, Immuno Rheumatology, CHU Montpellier, CHU Marseille,